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To assess the prevalence and isotypes of anti-nodal/paranodal antibodies to nodal/para-
nodal proteins in a large chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP) cohort, compare clinical features in seronegative vs seropositive patients, and
gather evidence of their isotype-specific pathogenic role.
Methods
Antibodies to neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1
(CNTN1), and contactin-associated protein 1 (Caspr1) were detected with ELISA and/or cell-
based assay. Antibody pathogenicity was tested by immunohistochemistry on skin biopsy,
intraneural injection, and cell aggregation assay.
Results
Of 342 patients with CIDP, 19 (5.5%) had antibodies against Nfasc155 (n = 9), Nfasc140/
186 and Nfasc155 (n = 1), CNTN1 (n = 3), and Caspr1 (n = 6). Antibodies were absent
from healthy and disease controls, including neuropathies of different causes, and
were mostly detected in patients with European Federation of Neurological Societies/
Peripheral Nerve Society (EFNS/PNS) definite CIDP (n = 18). Predominant antibody
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undetectable (n = 2). IgG4 antibody-associated phenotypes included onset before 30 years, severe neuropathy, subacute
onset, tremor, sensory ataxia, and poor response to intravenous immunoglobulin (IVIG). Immunosuppressive treatments,
including rituximab, cyclophosphamide, and methotrexate, proved effective if started early in IVIG-resistant IgG4-
seropositive cases. Five patients with an IgG1, IgG3, or undetectable isotype showed clinical features indistinguishable
from seronegative patients, including good response to IVIG. IgG4 autoantibodies were associated with morphological
changes at paranodes in patients’ skin biopsies. We also provided preliminary evidence from a single patient about the
pathogenicity of anti-Caspr1 IgG4, showing their ability to penetrate paranodal regions and disrupt the integrity of the
Nfasc155/CNTN1/Caspr1 complex.
Conclusions
Our findings confirm previous data on the tight clinico-serological correlation between antibodies to nodal/paranodal proteins
and CIDP. Despite the low prevalence, testing for their presence and isotype could ultimately be part of the diagnostic workup in
suspected inflammatory demyelinating neuropathy to improve diagnostic accuracy and guide treatment.
Classification of evidence
This study provides Class III evidence that antibodies to nodal/paranodal proteins identify patients with CIDP (sensitivity 6%,
specificity 100%).
Chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP), the most commonly acquired inflammatory neuropa-
thy worldwide, is clinically heterogeneous. Proven treatments
for CIDP include corticosteroids, plasma exchange, and in-
travenous immunoglobulin (IVIG). The response rates to
treatments were reported to be heterogeneous in subgroups of
patients, and the availability of specific biomarkers could provide
guidance for patient-tailored immunotherapeutic options.1
Antibodies to cell adhesion molecules of the paranodal complex,
neurofascin-155 (Nfasc155), contactin-1 (CNTN1), and
contactin-associated protein 1 (Caspr1), and to nodal
neurofascin-140/186 (Nfasc140/186) have been identified in
various percentages of patients with CIDP, with IgG4 being the
predominant isotype of these antibodies.2–8 Moreover, IgG4-
seropositive patients show specific clinical features and a poor
response to IVIG.
The prevalence of anti-CNTN1 and Nfasc155 IgG4 has been
well documented in cohorts of Japanese patients.2,5,6,9,10 It has
been shown that anti-CNTN1 IgG4 antibodies are pathogenic in
animal models and have a function-blocking activity.11,12 More-
over, anti-CNTN1 and Nfasc155 IgG4 are associated with spe-
cific alterations of the paranodal axo-glial contacts in nerve
biopsies,13,14 suggesting that these antibodies induce conduction
defects in patients by altering paranode integrity, hence the term
paranodopathy. In Europe, the study of these antibodies has been
so far limited to small cohorts of Spanish, French, and German
patients with CIDP,3,4,15,16 and there is little information on the
role and associated clinical features of antibodies of the IgG1-3
isotype.Moreover, the prevalence of anti-Caspr1 antibodies is still
largely unknown, as well as their possible pathogenic role.
Here, we assessed the prevalence and isotypes of antibodies
against Nfasc155, Nfasc140/186, CNTN1, and Caspr1 in
a large cohort of Italian patients affected by CIDP to better
characterize their clinical associations. We also investigated
skin biopsies from antibody-reactive patients for morpho-
logical abnormalities and the pathogenicity of anti-Caspr1
antibodies using in vitro and in vivo models.
Methods
Patients and sera
The primary research question of this study is to test the frequency
of antibodies to nodal/paranodal proteins in CIDP (Class III ev-
idence). Sera from 342 patients fulfilling the diagnostic criteria for
CIDP17 (306 typical and 36 atypical) were collected in 11 Italian
centerswith specific expertise in neuromuscular disorders andwere
all tested by ELISA and cell-based assay (CBA) for antibodies to
Nfasc155 and CNTN1 and by CBA only for antibodies to
Nfasc140/186 and Caspr1 by 2 independent laboratories (Istituto
di Ricovero e Cura a Carattere Scientifico [IRCCS] Mondino
Foundation, National Neurological Institute of Pavia, Italy, and
Institute for Neurosciences of Montpellier, France). As controls,
Glossary
Caspr1 = contactin-associated protein 1; CBA = cell-based assay; CIDP = chronic inflammatory demyelinating
polyradiculoneuropathy; CNTN1 = contactin-1; EFNS/PNS = European Federation of Neurological Societies/Peripheral
Nerve Society; GBS = Guillain-Barré syndrome; GFP = green fluorescent protein; HC = healthy control; IVIG = intravenous
immunoglobulin; MMN = multifocal motor neuropathy; MRC = medical research council; Nfasc155 = neurofascin-155;
ONLS = Overall Neuropathy Limitation Scale; PN = peripheral neuropathy.
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samples from healthy controls (HCs, n = 60); patients with
Guillain-Barré syndrome (GBS, n = 31), multifocal motor neu-
ropathy (MMN, n = 13), inherited neuropathy (n = 18), other
noninflammatory neuropathy (n = 52) including para-
proteinemic neuropathy (n = 18) and toxic-metabolic neuropa-
thy (n = 34), and patients with MS (n = 60) were tested.
Methods for ELISA18 and CBA6,10 were previously reported and
are available as supplementary methods, links.lww.com/NXI/
A165. Clinical information was collected from seropositive
patients with CIDP and from 64 randomly selected seronegative
patients with CIDP. Weakness was graded as mild if the medical
research council (MRC) score of the weakest muscle considered
of either proximal or distal muscle groups was <5 and >3,
moderate ifMRC= 3, or severe ifMRC<3. Disability was graded
using the Overall Neuropathy Limitation Scale (ONLS).19 Re-
sponse to treatment was investigated post hoc and was defined as
a persistent improvement of disability with anONLS change after
treatment ≥1. Reactivity of sera to teased fibers from murine
sciatic nerves was also evaluated as previously described.2
Immunohistochemistry on skin biopsy
Three patients with anti-Nfasc155 IgG4 antibodies, 1 patient
with anti-CNTN1 IgG3/IgG4 antibodies, 1 patient with anti-
Caspr1 IgG4 antibodies, 1 patient with anti-Nfasc155 antibodies
of an undetectable isotype, and 6 seronegative patients with
CIDP underwent 3-mmpunch skin biopsies at 1 distal site of the
lower limb as per EFNS/PNS guidelines.20 Nodal/internodal
morphological analysis was performed by double immunofluo-
rescence staining for myelin basic protein and Nfasc or myelin
basic protein and Caspr1. Detailed methods are available in
supplementary methods, links.lww.com/NXI/A165.
Purification of patients’ antibodies
For in vitro and in vivo studies, IgG1 and IgG4 were purified
from the serum of 1 Caspr1-reactive patient and the plasma of
a HC and their pathogenicity was tested by intraneural in-
jection on murine sciatic nerve and cell aggregation assay.
Methods for in vitro and in vivo studies are detailed in sup-
plementary methods, links.lww.com/NXI/A164.
Statistics
Clinical data were presented as number (%) ormean (min-max).
Categorical variables were compared in seronegative and sero-
positive patients using the χ2 test or Fisher exact test; unpaired
2-tailed Student t test was used for comparing continuous vari-
ables. Analysis of clinical variables was performed using STATA.
p values inferior to 0.05 were considered significant.
Standard protocol approvals, registrations,
and patient consents
The study was approved by local institutional ethical com-
mittees. Written informed consent was obtained from all
patients (or guardians of patients) participating in the study.
Data availability
Anonymized data from this study will be shared by request
from any qualified investigator.
Results
Serologic findings
Of 342 sera from patients with CIDP tested, 10 (3%) were
positive for antibodies to anti-Nfasc155 using ELISA and
CBA (figure 1A). IgG isotypes were IgG4 in 7, IgG3 in 1, and
undetectable in 2 patients (figure 1B). One of these latter
patients showed IgG4 reactivity against Nfasc140/186 and
was thus considered a Nfasc140/186-reactive patient. Three
patients (1%) tested positive on ELISA and CBA for anti-
CNTN1 antibodies (figure 1A). IgG isotypes were IgG4 in 2
patients and mixed IgG3/IgG4 in 1 patient (figure 1B). All
sera reactive to Nfasc155 or CNTN1 by ELISA were also
confirmed by CBA, and no nonspecific reactivities by ELISA
only were identified. Six patients (2%) showed reactivity
against Caspr1 on CBA (figure 1C). Three had an IgG4-
predominant isotype, 2 had an IgG1 isotype, and 1 did not
have a detectable isotype. Overall, 19 patients (6%) had
antibodies against one of these 4 targets. None of the HCs and
patients with GBS, MMN, hereditary neuropathy, other
noninflammatory neuropathies, or MS tested positive, in-
dicating that the presence of antibodies to nodal/paranodal
proteins accurately identify patients with CIDP with sensi-
tivity 6% and specificity 100%. Of note, none of the sera from
36 atypical CIDP cases tested positive.
Sera from patients with IgG4 anti-Nfasc155, anti-CNTN1, or
anti-Caspr1 antibodies, but not anti-Nfasc155 of the IgG3
isotype or undetectable isotype, consistently showed re-
activity against paranodes when tested on teased fibers from
murine sciatic nerves (figure 1D). Sera with anti-Nfasc140/
186 IgG4 that co-reacted against Nfasc155 stained the nodes
of Ranvier on teased fibers.
Clinical features
Patients with anti-Nfasc155 IgG4 antibodies
Of patients with anti-Nfasc155 IgG4 antibodies, 4 were men
and 3 were women, with an average age at onset of 31 ± 18
years (table e-1, links.lww.com/NXI/A164). The onset of
neuropathy was subacute in 5 patients. One case was initially
diagnosed with GBS.
All patients had symmetric 4-limb muscle weakness, which was
mild to moderate in the upper limbs and proximal muscles of
the lower limbs but severe in 5 patients in the lower limb distal
muscles. Pinprick and position sense at the hallux were reduced
or abolished in all patients. Tremor was also invariably present,
and 6 had sensory ataxia. One patient reported neuropathic pain
at onset, and 1 had dysphagia. One of them presented optic
neuritis during steroid tapering. Brain MRI was thus performed
but did not show evidence of disseminated inflammatory CNS
disease. The neuropathy was moderately to severely disabling
with an ONLS at onset of 5.8 ± 2.2. Two patients required
a wheelchair 1 month after the disease onset. The patients
received IVIG (n = 6), steroids (n = 7), azathioprine (n = 1), or
rituximab (n = 1). Only 1 patient responded to IVIG and
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Figure 1 Reactivity to Nfasc155, CNTN1, and Caspr1 in CIDP by ELISA and CBA
(A) Serum samples from patients with CIDP (n = 342), MMN (n = 13), GBS (n = 31), genetic PN (n = 18), other noninflammatory PN (n = 52), MS (n = 60) and from
HCs (n = 60)were tested for autoantibodies to humanNfasc155 (left) andCNTN1 (right) by ELISA. ODare shown after subtraction of the baselineOD reading to
bovine serum albumin. The red line represents themean OD in HCs plus 3 standard deviations. (B) IgG isotype in Nfasc155- and CNTN1-positive patients. (C)
The sera (here case 14) were tested on living HEK cells transfectedwith CNTN1 and Caspr1 (red) and then revealedwithmouse antihuman IgG1, IgG2, IgG3, or
IgG4 (green) as indicated. Nuclei were stainedwith DAPI (blue). (D) These are teased fibers frommouse sciatic nerves immunostained for CNTN1 (red) and the
serum from case 14, then revealed with mouse antihuman IgG1, IgG2, IgG3, or IgG4 (green) as indicated. IgG1 and IgG4 from this patient reacted against
Caspr1 and bound to the paranodal regions. Scale bars: 10 μm. Caspr1 = contactin-associated protein 1; CBA = cell-based assay; CIDP = chronic inflammatory
demyelinating polyradiculoneuropathy; CNTN1 = contactin-1; GBS = Guillain-Barré syndrome; HC = healthy control; HEK = human embryonic kidney; MMN =
multifocal motor neuropathy; Nfasc155 = neurofascin-155; OD = Optical density; PN = peripheral neuropathy.
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steroids (ONLS 4→ 2), 1 patient showed response to steroids
(ONLS 6 → 2), and 1 patient unresponsive to IVIG and ste-
roids had sustained response after rituximab (ONLS 9 → 2).
Patients with anti-CNTN1 IgG4 antibodies
Of patients with anti-CNTN1 IgG4 antibodies, 3 were men
with a mean age at onset of 56 ± 26 years (table e-1, links.lww.
com/NXI/A164). The onset of neuropathy was subacute in 2
patients. Strength was impaired in both proximal and distal
muscles in the upper and lower limbs, often to a severe degree,
and 2 of them required a wheelchair. Pinprick sensation and
proprioception were either severely reduced or abolished, and
all of them had sensory ataxia. One patient showed cranial
nerve involvement and respiratory failure. One patient with
anti-CNTN1 IgG3/IgG4 antibodies had a concurrent onset of
CIDP and nephrotic syndrome because of membranous glo-
merulonephritis. A kidney biopsy showed subepithelial
deposits of immune complexes and complement deposition.
CNTN1 patients had the highest disability at onset with an
ONLS of 7.6 ± 2.5. One patient died of cardiac disease 6
months after the disease onset. The patients were treated with
IVIG (n = 3), steroids (n = 3), plasma exchange (n = 2), and
immunosuppressive drugs (n = 2). None of them had a sus-
tained response to either IVIG or steroids. Cyclophosphamide
was effective in 2 patients, leading to significant improvement
of the neuropathy in 1 case and complete remission of the
neuropathy together with regression of the nephrotic syn-
drome in the other case, who did not require further treatment.
Patients with anti-Caspr1 IgG4 antibodies
Of seropositive patients with anti-Caspr1 IgG4 antibodies, 2
were men and 1 was a woman, with a mean age at onset of 43 ±
17 years (table e-1, links.lww.com/NXI/A164). The onset was
subacute in 2 patients. Weakness was mild to moderate in
proximal muscle groups and moderate to severe in distal
muscle groups in both upper and lower limbs. Pinprick sen-
sation was reduced, and position sense was abolished at the
hallux in all of them. None of them reported neuropathic pain.
One patient complained of dysphagia, and 1 patient had
tremor. The disease was severe, with ameanONLS of 8.3 ± 0.6.
The patients were treated with IVIG (n = 3), steroids (n = 3),
plasma exchange (n = 1), methotrexate (n = 1), and interferon-
alfa (n = 1). A sustained response was observed only in 1
patient receiving steroids andmethotrexate (ONLS 9→ 6) and
1 patient treated with interferon-alfa (ONLS 8 → 7).
Seropositive patients with an IgG1-3 isotype or
undetectable IgG isotype
Six patients had IgG1 or IgG3 antibodies or an undetectable IgG
isotype against Nfasc155 (n = 3) or Caspr1 (n = 3) (table e-1,
links.lww.com/NXI/A164). One of these patients presented
antibodies reacting to both Nfasc155 and Nfasc140/186. The
clinical features of this patient, mainly consisting in a very early
onset IVIG-responsive neuropathy, have been previously de-
tailed.16 We will thus focus here on the 5 other patients, 2 men
and 3 women. In 2 of them, both reactive against Caspr1, the
disease started in the first decade of life. The mode of onset was
subacute in 1 patient only. If present, weakness was graded as
mild to moderate in upper limbs and proximal muscles of lower
limbs. All 5 patients had weakness in lower limb distal muscles,
which was severe in 2 of them. Pinprick sensation was reduced
in 3 and position sense was reduced at the hallux in 2 patients,
but none had absent proprioception. Sensory ataxia was
reported in 4 patients, 2 with anti-Nfasc155 antibodies and 2
with anti-Caspr1 antibodies, whereas tremor was observed in 2
patients with anti-Caspr1 antibodies. Disability was usually low
with a mean ONLS at onset of 3.2 ± 1.3. Only 1 case with anti-
Caspr1 antibodies needed walking aids. The patients were
treated with IVIG (n = 4) and steroids (n = 2). One patient with
minimal disability did not require treatment. Three of 4 patients
treated with IVIG had a good response.
Comparison of seropositive vs seronegative patients
We compared the clinical features and responses to treat-
ments of patients with IgG4 antibodies against Nfasc155,
CNTN1, or Caspr1 with those of 64 randomly selected
patients with CIDP who were negative for antibodies against
Nfasc155, Nfasc140/186, CNTN1, or Caspr1. We also
compared seropositive patients with an IgG1, IgG3, or un-
detectable IgG isotype with seronegative patients (table 1).
Anti-Nfasc155 and anti-Caspr1 IgG4 seropositive patients had
more frequently an early disease onset, before 30 years of age,
as opposed to that of anti-CNTN1 IgG4 seropositive patients
and seronegative patients. A subacute onset was reported in up
to two-thirds of anti-Nfasc155, anti-CNTN1, and anti-Caspr1
IgG4 seropositive patients compared with 28% of seronegative
patients. According to the EFNS/PNS criteria, CIDP pheno-
type was typical in all IgG4-seropositive patients. Tremor was
invariably present in patients with anti-Nfasc155 IgG4 anti-
bodies but was also observed in anti-CNTN1 and anti-Caspr1
IgG4 seropositive patients. Severe proprioceptive loss and
sensory ataxia were significantly more frequent in IgG4-
seropositive patients and were observed in all patients with
anti-CNTN1 antibodies, 2 patients with anti-Caspr1 IgG4
antibodies, and 3 patients with anti-Nfasc155 IgG4 antibodies
(table 1). In anti-CNTN1 and anti-Caspr1 IgG4 seropositive
patients, weakness was usually graded as moderate to severe
across proximal and distal muscle groups, whereas in patients
with anti-Nfasc155 IgG4 antibodies, motor impairment
showed a characteristic distal predominance in the lower limbs.
A higher level of CSF total protein and the presence of tem-
poral dispersion on nerve conduction studies were also char-
acteristic features of patients with autoantibodies of the IgG4
isotype. IgG4-seropositive patients had a higher disability at
onset: 5 patients needed a walking aid, and 5 patients required
a wheelchair. In particular, patients with anti-CNTN1 or anti-
Caspr1 IgG4 antibodies showed the highest disability at onset.
Patients with anti-Nfasc155, CNTN1, or Caspr1 IgG4 anti-
bodies had a lower response rate to IVIG compared with
seronegative patients (8% vs 67%, p < 0.001), but there was
no remarkable difference in the response to steroids or
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Table 1 Clinical features of patients with CIDP and antibodies to Nfasc155, CNTN1, and Caspr1
Autoantibody
seronegative (N = 64)
Anti-paranodal
proteins IgG4 (N = 13)
Anti-Nfasc155
IgG4 (N = 7)
Anti-CNTN1
IgG4 (N = 3)
Anti-Caspr1







Age at onset 39 (18–64) 36 (13–82) 22 (13–63) 58 (30–82) 46 (24–57) 56 (7–74)
Early onset (below
30 years of age)
7 (11%) 5 (38%)a 4c 0 1 2 (40%)
Male sex 42 (66%) 9 (69%) 4 3 2 2 (40%)
Other autoimmune
disease
8 (12.5%) 3 (23%) 2 1 0 1 (20%)
M protein 15 (23%) 0 (0%) 0 0 0 0 (0%)
Triggering infection/
vaccination
11 (17%) 3 (23%) 2 0 1 0 (0%)
Clinical phenotype
Typical 52 (81%) 13 (100%) 7 3 3 5 (100%)
Atypical 12 (19%) 0 (0%) 0 0 0 0 (0%)
Subacute onset 18 (28%) 9 (69%)b 5a 2 2 1 (20%)
Weakness
moderate/severe
UL proximal 12 (19%) 4 (31%) 0 2 2 0 (0%)
UL distal 32 (50%) 8 (61%) 3 2 3 1 (20%)
LL proximal 16 (25%) 6 (46%) 1 2 3 1 (20%)
LL distal 37 (58%) 12 (92%)a 7a 2 3 3 (60%)
Pinprick sensation
at the hallux
Reduced 43 (67%) 10 (83%) 5 3 3 3 (60%)
Abolished 2 (3%) 1 (8%) 1 0 0 0 (0%)
Position sensation
at the hallux
Reduced 27 (43%) 4 (30%)b 3 0 1 2 (40%)
Abolished 8 (13%) 8 (61%)b 3 3a 2 0 (0%)
Sensory ataxia 22 (35%) 11 (85%)b 6a 3a 2 4 (80%)
Tremor 8 (12%) 9 (69%)c 7c 1 1 2 (40%)
Pain 23 (36%) 3 (23%) 1 2 0 0 (0%)
CSF protein 96 (24–55) 350 (128–679)c 278 (142–679) 148 (128–350) 426 (343–510) 68 (45–586)
ONLS 5 (1–11) 8 (3–10)a 5 (3–9) 8 (5–10) 8 (8–9) 3 (2–5)
NCS features
Prolonged DML 30 (51%) 9 (70%) 5 1 3 5 (100%)
Reduced CV 52 (88%) 11 (85%) 5 3 3 5 (100%)
Prolonged F wave 35 (62%) 4 (36%) 3 0 1 4 (100%)
Conduction
blocks
30 (51%) 5 (42%) 3 1 1 3 (60%)
Temporal
dispersion
15 (25%) 7 (64%)a 4 2 1 4 (80%)a
Continued
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immunosuppressive treatment. In particular, 1 patient with anti-
Nfasc155 IgG4 antibodies was treated with rituximab, 1 patient
with anti-Nfasc155 IgG4 antibodies was treated with azathio-
prine, 2 patients with anti-CNTN1 IgG4 antibodies were treated
with cyclophosphamide, and 1 patient with anti-Caspr1 IgG4
antibodies was treatedwithmethotrexate. Four of themwhowere
started on immunosuppressors within 1 year from disease onset
showed long-lasting good response.
Patients with antibodies to Nfasc155, CNTN1, or Caspr1 of the
IgG1, IgG3, or undetectable isotype did not show distinct clinical
features or response to treatments compared with seronegative
patients, except for more frequent temporal dispersion on nerve
conduction studies.
Morphological changes of the nodes of Ranvier in skin
biopsy of seropositive patients
We evaluated skin biopsies from 3 patients with anti-Nfasc155
IgG4 antibodies, 1 patient with anti-CNTN1 IgG3/IgG4
antibodies, 1 patient with anti-Caspr1 IgG4 antibodies, 1 pa-
tient with anti-Nfasc155 antibodies of an undetectable isotype,
and 6 seronegative patients with CIDP. Analysis of myelinated
fibers from patients with anti-Nfasc155 and anti-Caspr1 IgG4
showed elongation of the nodes of Ranvier and loss of para-
nodal Nfasc155 and Caspr1 staining. Moderate elongation of
the nodes of Ranvier and loss of Nfasc155 paranodal staining
were also observed in myelinated fibers of the patient with anti-
CNTN1 IgG3/IgG4 antibodies. Contrarily, we did not observe
similar changes in the patient with anti-Nfasc155 antibodies
with an undetectable isotype, seronegative patients CIDP, or
HCs (figure 2).
Pathogenic effects of anti-Caspr1 IgG4 and IgG1
antibodies
Anti-CNTN1 IgG4 antibodies were previously found to have
function-blocking activity and to disrupt the interaction be-
tween CNTN1 and its glial partner Nfasc155.12 We have
previously shown that anti-CNTN1 IgG4 and anti-Nfasc155
Table 1 Clinical features of patients with CIDP and antibodies to Nfasc155, CNTN1, and Caspr1 (continued)
Autoantibody
seronegative (N = 64)
Anti-paranodal
proteins IgG4 (N = 13)
Anti-Nfasc155
IgG4 (N = 7)
Anti-CNTN1
IgG4 (N = 3)
Anti-Caspr1








No 4 (7%) 4 (31%)c 1 2 1 0 (0%)
Partial/transitory 14 (26%) 8 (61%)c 5 1 2 1 (25%)
Good 37 (67%) 1 (8%)c 1a 0b 0 3 (75%)
Response to
steroids
No 14 (28.5%) 3 (25%) 0 2 1 1 (50%)
Partial/transitory 21 (43%) 6 (50%) 4 1 1 1 (50%)
Good 14 (28.5%) 3 (25%) 2 0 1 0 (0%)
Response to PEX
No 1 (8%) 2 (67%) 0 1 1 0 (0%)
Partial/transitory 6 (46%) 0 (0%) 0 0 0 0 (0%)




No 5 (19%) 0 (0%) 0 0 0 0 (0%)
Partial/transitory 13 (50%) 1 (20%) 1 0 0 0 (0%)
Good 8 (31%) 4 (80%) 1 2 1 0 (0%)
Abbreviations: Caspr1 = contactin-associated protein 1; CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; CNTN1 = contactin-1; CV =
conduction velocity; DML = distal motor latency; IVIG = intravenous immunoglobulin; LL = lower limb; NCS = nerve conduction study; Nfasc155 = neurofascin-
155; ONLS = Overall Neuropathy Limitation Scale; PEX = plasma exchange; UL = upper limb.
a p < 0.05.
b p < 0.01.
c p < 0.005.
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IgG4 antibodies are pathogenic and disrupt the paranodal
regions.11,21 We thus examined whether anti-Caspr1 antibodies
also affect the integrity of the CNTN1/Caspr1/Nfasc155
complex. In particular, we purified IgG1 and IgG4 and tested
the effects of the different antibody isotypes. First, we tested the
impact of IgG4 and IgG1 fractions fromCaspr1-positive patients
on the interaction of CNTN1/Caspr1 with Nfasc155 by a cell
aggregation assay (figure 3). Human embryonic kidney cells
were transfected with Nfasc155 and mCherry and incubated for
2 hours with cells coexpressing CNTN1/Caspr1 and green
fluorescent protein (GFP). The percentage of cell clusters
showing contacts between red and green cells and the percent-
age of green and red cells per cell clusters were quantified. As
a negative control, Nfasc155-mCherry-transfected cells were
incubated with cells expressing GFP only. In the absence of
CNTN1/Caspr1, Nfasc155-expressing cells do not form signif-
icant contact with GFP-expressing cells, and most clusters
express only green or red cells. The expression of CNTN1/
Caspr1 significantly increases the number of clusters with con-
tacts, andmost cell clusters show an average of 50% of CNTN1/
Caspr1- and 50% of Nfasc155-expressing cells. The presence of
10 μg of IgG4 from a Caspr1-positive patient, but not IgG1,
abolished the interaction between CNTN1/Caspr1- and
Nfasc155-expressing cells to the level of negative controls, thus
supporting a blocking function of anti-Caspr1 IgG4 antibodies.
To further confirm these findings, mouse sciatic nerve segments
were incubated in vitro with 10 μg of IgG4 or IgG1 fractions
from Caspr1-positive patients for 3 hours, and IgG deposition
was monitored. IgG4 but not IgG1 antibodies were found to
penetrate the paranodal regions (figure 4). These findings were
replicated in vivo by performing intraneural injections. Again,
only IgG4 antibodies were found to penetrate the paranodal
regions. Of interest, the level of antibody penetration across the
Figure 2 Morphological alterations of the nodes of Ranvier in patients with CIDP with IgG4 autoantibodies
We evaluated skin biopsies from 3 patients with IgG4 anti-Nfasc155 antibodies, 1 patient with IgG3/IgG4 anti-CNTN1 antibodies, 1 patient with IgG4 anti-
Caspr1 antibodies, 1 patient with undetectable isotype IgG anti-Nfasc155, and 6 seronegative patients with CIDP. Analysis of myelinated fibers showed
elongation of the nodes of Ranvier and loss of paranodal Nfasc155 staining in skin biopsies from patients with anti-Nfasc155 (C) and Caspr1 (E) IgG4.
Moderate elongation of the nodes of Ranvier and loss of Nfasc155 paranodal staining were also observed inmyelinated fibers of a CNTN1 IgG3/IgG4-positive
patient (D). Contrarily, we did not observe similar changes in the patient with undetectable isotype IgG anti-Nfasc155 antibodies (F), in seronegative patients
with CIDP (B), or in HCs (A). A complete loss of Caspr1 staining was observed in biopsies from patients with IgG4 antibodies to paranodal proteins (I, L, M), but
not in an Nfasc155 seropositive patient with an undetectable isotype (N) and in seronegative CIDP (H) or healthy patients (G). Caspr1 = contactin-associated
protein 1; CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; CNTN1 = contactin-1; HC = healthy control; Nfasc155 = neurofascin-155.
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paranodal region was similar at 1 or 3 days after intraneural
injection, and IgG4 depositionwas detected only at the border of
the nodes of Ranvier (figure 4). No paranodes presented
a complete invasion by IgG4 at 1 or 3 days postinjection.
Discussion
Antibodies to nodal/paranodal protein were found, albeit with
a low frequency, in Italian patients with CIDP and are associ-
ated with target- and isotype-specific clinical features, as
previously reported. The prevalence of anti-Nfasc155 and anti-
CNTN1 antibodies was similar to that reported by previous
studies in European patients but was lower compared with that
in Japanese patients.5,10 The discrepancymay be attributable to
differences in inclusion criteria, ethnicities, and non-
standardized laboratory techniques. The frequency of anti-
Caspr1 IgG4 antibodies was equal to that of antibodies against
CNTN1, confirming that Caspr1 may also represent a relevant
target of the immune response in Caucasian patients with
CIDP. None of the healthy or pathologic controls tested, in-
cluding patients affected by other neuropathies, showed re-
activity against Nfasc155, CNTN1, or Caspr1. These
maximum levels of specificity entail that the tests perform very
well for the diagnosis of such CIDP subtypes.
In addition, it is worth noting that the results of antibody
testing by ELISA and CBA were concordant in all samples
across the 2 testing centers in Pavia and Montpellier, in-
dicating that these techniques, although not broadly available,
have a high reproducibility if performed in specialized centers.
Our findings largely confirm previous observations by several
groups showing a tight clinical serologic correlation of anti-
bodies to nodal/paranodal proteins and clinical features of
seropositive patients with CIDP.
The patients with anti-Nfasc155 IgG4 antibodies showed
earlier onset, distal predominant lower limb weakness, and
gait disturbance. Tremor was also present, although only in 1
case this was disabling. One patient with such antibodies
developed bilateral optic neuritis during steroid tapering 18
months after the onset of the neuropathy.
The patients with anti-CNTN1 antibodies were older and
showed a subacute or rapidly progressive severe sensory and
motor neuropathy. Previous studies found that anti-CNTN1
antibodies were associated with either predominant motor or
sensory impairment. Here, both sensory and motor fibers were
equally severely affected, and the patients became wheelchair
dependent few months after the disease onset. Notably, 1 pa-
tient with anti-CNTN1 antibodies of IgG3 and IgG4 subclasses
showed the contemporary occurrence of membranous glo-
merulonephritis. This association had been reported in 3 cases
with anti-CNTN1 antibodies,7,22,23 and either a direct damage
Figure 3 IgG4 to Caspr1 disrupt the interaction between Nfasc155 and CNTN1/Caspr1
(A–D) HEK cells transfected with CNTN1 and Caspr1 (green) or Nfasc155 (red) were incubated together for 2 hours in the presence of control IgG4 (B), anti-
Caspr1 IgG1 (C), or anti-Caspr1 IgG4 (D). As negative controls, HEK cells transfected with Nfasc155 (red) were incubated with cells transfected with GFP (A).
Anti-Caspr1 IgG4, but not anti-Caspr1 IgG1, abrogated the aggregation of Nfasc155-transfected cells with CNTN1/Caspr1. Scale bar: 10 μm. (E–F) The graphs
represent the relative frequency of green cells per aggregates (n = 4 experiments for each condition). The percentage of cell clusters with contacts between
green and red cells was quantified (F). The percentage of contacts was significantly decreased in the presence of anti-Caspr1 IgG4 (p < 0.005 by unpaired 2-
tailed Student t tests and by one-way ANOVA, followed by Bonferroni post hoc tests). Bars represent mean and SEM. ANOVA = analysis of variance; Caspr1 =
contactin-associated protein 1; CNTN1 = contactin-1; GFP = green fluorescent protein; HEK = human embryonic kidney; Nfasc155 = neurofascin-155.
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or indirect damage, after the deposition of immune complexes,
can be hypothesized. Of interest, a recent study showed that
complement depositionmay contribute to the pathophysiology
of anti-CNTN1-associated neuropathy, particularly in patients
with a predominance of the IgG3 subclass.24
Neuropathy in patients with anti-Caspr1 IgG4 antibodies was
also highly debilitating. Pain did not seem to be a clinical
feature associated with the presence of anti-Caspr1 antibodies
in our series, as opposed to the first report of 2 patients with
Caspr1-associated inflammatory neuropathy.8
As a novel observation of our study, we found that patients with
anti-Nfasc155 or Caspr1 antibodies of the IgG1, IgG3, or un-
detectable IgG isotype did not show clinical features distinct
from seronegative patients. Most importantly, patients with
anti-Nfasc155, CNTN1, or Caspr1 IgG4 antibodies, but not
patients with antibodies to Nfasc155 or Caspr1 of IgG1, IgG3,
or undetectable IgG isotype, showed a significantly lower re-
sponse rate to IVIG compared with seronegative patients.
Analysis of myelinated fibers in the skin biopsy of patients with
anti-Nfasc155, CNTN1, or Caspr1 IgG4 antibodies showed
morphological changes of the nodes of Ranvier, including
elongation of the node and loss of neurofascin and Caspr1
staining at paranodes, which were absent or less prominent in
seronegative CIDP cases or in the case with anti-Nfasc155
antibodies of an undetectable isotype. These data add to other
recent histopathologic and neurophysiologic observations in
patients with antibodies to nodal/paranodal proteins14,25 and
indicate that isotype determination appears to be crucial to
correctly identify such patients and to guide treatment.
The high frequency of anti-Caspr1 antibodies in our series
prompted us to further investigate their pathogenic effects.
Albeit the experimental setting was limited to the examination
of the effects of anti-Caspr1 autoantibodies from a single pa-
tient, we found that anti-Caspr1 IgG4, but not anti-Caspr1
IgG1, antibodies affect the interaction between the CNTN1/
Caspr1 and Nfasc155 complex using a cell aggregation assay.
These findings are in line with the previously reported patho-
genic role of anti-CNTN1 IgG4 antibodies11,12 and suggest
that IgG4 antibodies targeting the CNTN1/Caspr1 complex
may have a function-blocking activity and disrupt the paranodal
axo-glial contact. In keeping with this experimental evidence,
our data also seem to indicate that anti-Caspr1 IgG4 antibodies
can penetrate the paranodal regions. It is worth noting that the
pathogenic mechanism of IgG4 antibodies in other diseases
Figure 4 Anti-Caspr1 IgG4, but not IgG1, invades the paranodal regions
(A–C) Sciatic nerve fibers were incubated in vitro
with purified control IgG4 (A), anti-Caspr1 IgG1
(B), or anti-Caspr1 IgG4 (C) for 3 hours and
immunolabeled for IgG (green) and CNTN1 (red).
(D–F) Sciatic nerves were fixed 1 or 3 days after
intraneural injections of purified control IgG4 (D),
anti-Caspr1 IgG4 (E–F), immunolabeled for
CNTN1 (red), and human IgG (green). Note that
only anti-Caspr1 IgG4 penetrated the paranodes.
One or 3 days after injection, IgG4 antibodies
were detected at the paranode borders (arrows).
Images are representative of 3 independent
experiments. Scale bar: 10 μm. Caspr1 = con-
tactin-associated protein 1; CNTN1 = contactin-1.
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implicates the disruption of cell adhesion protein complexes
too, by inhibiting protein-protein interaction, and that thera-
pies aiming at downregulating the humoral immune response,
such as rituximab, showed some efficacy in anti-Nfasc155- and
anti-Caspr1 antibody-associated CIDP, as well as in other
IgG4-related diseases, likely because of the depletion of the
Nfasc155- or Caspr1-reactive B cells.26
Despite the limitation entailed by the retrospective data
collection, in the present series, immunosuppressive treat-
ment, including rituximab, cyclophosphamide, and metho-
trexate, seemed effective in IVIg-resistant IgG4 seropositive
patients if started early in the disease course. Of note, we did
not detect a significant difference in the response to steroids
between patients with anti-paranodal IgG4 antibodies and
seronegative patients, confirming steroids as an effective
therapeutic option in CIDP cases, independent from their
serologic status for anti-Nfasc155, CNTN1, or Caspr1
antibodies. Low numbers of patients treated with plasma
exchange, and the temporal overlap of plasma exchange
cycles with other treatments (case 12), prevented us from
drawing firm conclusions on its role in patients with anti-
paranodal IgG4 antibodies.
Although patients with antibodies against the nodal/
paranodal component often, albeit not always, show addi-
tional clinical features, CIDP phenotype was typical in all
IgG4 and non-IgG4 seropositive patients according to the
EFNS/PNS criteria, whereas none of the sera from atypical
CIDP cases or control sera showed the presence of these
antibodies. Together, this observation challenges the view
that the search for antibodies against the nodal/paranodal
component may be limited to atypical CIDP cases.
Testing for the presence of antibodies against Nfasc155,
CNTN1, and Caspr1, followed by IgG isotype determination
in seropositive cases should be part of the diagnostic workup
in inflammatory neuropathies to improve diagnostic accuracy
and guide treatment. Moreover, knowledge of the mechanism
underlying these CIDP subtypes might shed light on the
pathophysiology and help further understanding of this
complex and heterogeneous disease.
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